Maazza Hussien1,2, Muzamil Mahdi Abdel Hamid2, Elamin Abdelkarim Elamin1, Abdalla O Hassan2, Arwa H Elaagip2, Abusofyan Hamattallah A Salama3, Mohammed H Abdelraheem2,4, Abdelrahim O Mohamed5. 1. Department of Medical Parasitology and Entomology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan. 2. Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. 3. Faculty of Medical Laboratory Sciences, North Kordofan University, Alobied, Sudan. 4. Ashworth Laboratories, School of Biological Sciences, University of Edinburgh, Edinburgh, United Kingdom. 5. Department of Biochemistry, Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Abstract
BACKGROUND: Current malaria control and elimination strategies rely mainly on efficacious antimalarial drugs. However, drug resistance is a major threat facing malaria control programs. Determination of drug resistance molecular markers is useful in the monitoring and surveillance of malaria drug efficacy. This study aimed to determine the mutations and haplotypes frequencies of different genes linked with antimalarial drug resistance in certain areas in Sudan. METHODS: A total of 226 dried blood spots (DBS) of microscopically diagnosed P. falciparum isolates were collected from Khartoum and three other areas in Sudan during 2015-2017. Plasmodium falciparum confirmation and multiplicity of infection was assessed using the Sanger's 101 SNPs-barcode and speciation was confirmed using regions of the parasite mitochondria. Molecular genotyping of drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, exonuclease, Pfk13, parasite genetic background (PGB) (Pfarps10, ferredoxin, Pfcrt, Pfmdr2)) was also performed. All genotypes were generated by selective regions amplicon sequencing of the parasite genome using the Illumina MiSeq platform at the Wellcome Sanger Institute, UK then genotypes were translated into drug resistance haplotypes and species determination. FINDINGS: In total 225 samples were confirmed to be P. falciparum. A higher proportion of multiplicity of infection was observed in Gezira (P<0.001) based on the Sanger 101 SNPs -barcode. The overall frequency of mutant haplotype Pfcrt 72-76 CVIET was 71.8%. For Pfmdr1, N86Y was detected in 53.6%, Y184F was observed in 88.1% and D1246Y was detected in 1.5% of the samples. The most frequently observed haplotype was YFD 47.4%. For Pfdhfr (codons 51, 59,108,164), the ICNI haplotype was the most frequent (80.7%) while for Pfdhps (codons 436, 437, 540, 581, 613) the (SGEAA) was most frequent haplotype (41%). The Quadruple mutation (dhfr N51I, S108N + dhps A437G, K540E) was the highest frequent combined mutation (33.9%). In Pfkelch13 gene, 18 non-synonymous mutations were detected, 7 of them were detected in other African countries. The most frequent Pfk13 mutation was E433D detected in four samples. All of the Pfk13 mutant alleles have not been reported to belong to mutations associated with delayed parasite clearance in Southeast Asia. PGB mutations were detected only in Pfcrt N326S\I (46.3%) and Pfcrt I356T (8.2%). The exonuclease mutation was not detected. There was no significant variation in mutant haplotypes between study areas. CONCLUSIONS: There was high frequency of mutations in Pfcrt, Pfdhfr and Pfdhps in this study. These mutations are associated with chloroquine and sulfadoxine-pyrimethamine (SP) resistance. Many SNPs in Pfk13 not linked with delayed parasite clearance were observed. The exonuclease E415G mutation which is linked with piperaquine resistance was not reported.
BACKGROUND: Current malaria control and elimination strategies rely mainly on efficacious antimalarial drugs. However, drug resistance is a major threat facing malaria control programs. Determination of drug resistance molecular markers is useful in the monitoring and surveillance of malaria drug efficacy. This study aimed to determine the mutations and haplotypes frequencies of different genes linked with antimalarial drug resistance in certain areas in Sudan. METHODS: A total of 226 dried blood spots (DBS) of microscopically diagnosed P. falciparum isolates were collected from Khartoum and three other areas in Sudan during 2015-2017. Plasmodium falciparum confirmation and multiplicity of infection was assessed using the Sanger's 101 SNPs-barcode and speciation was confirmed using regions of the parasite mitochondria. Molecular genotyping of drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, exonuclease, Pfk13, parasite genetic background (PGB) (Pfarps10, ferredoxin, Pfcrt, Pfmdr2)) was also performed. All genotypes were generated by selective regions amplicon sequencing of the parasite genome using the Illumina MiSeq platform at the Wellcome Sanger Institute, UK then genotypes were translated into drug resistance haplotypes and species determination. FINDINGS: In total 225 samples were confirmed to be P. falciparum. A higher proportion of multiplicity of infection was observed in Gezira (P<0.001) based on the Sanger 101 SNPs -barcode. The overall frequency of mutant haplotype Pfcrt 72-76 CVIET was 71.8%. For Pfmdr1, N86Y was detected in 53.6%, Y184F was observed in 88.1% and D1246Y was detected in 1.5% of the samples. The most frequently observed haplotype was YFD 47.4%. For Pfdhfr (codons 51, 59,108,164), the ICNI haplotype was the most frequent (80.7%) while for Pfdhps (codons 436, 437, 540, 581, 613) the (SGEAA) was most frequent haplotype (41%). The Quadruple mutation (dhfr N51I, S108N + dhpsA437G, K540E) was the highest frequent combined mutation (33.9%). In Pfkelch13 gene, 18 non-synonymous mutations were detected, 7 of them were detected in other African countries. The most frequent Pfk13 mutation was E433D detected in four samples. All of the Pfk13 mutant alleles have not been reported to belong to mutations associated with delayed parasite clearance in Southeast Asia. PGB mutations were detected only in Pfcrt N326S\I (46.3%) and Pfcrt I356T (8.2%). The exonuclease mutation was not detected. There was no significant variation in mutant haplotypes between study areas. CONCLUSIONS: There was high frequency of mutations in Pfcrt, Pfdhfr and Pfdhps in this study. These mutations are associated with chloroquine and sulfadoxine-pyrimethamine (SP) resistance. Many SNPs in Pfk13 not linked with delayed parasite clearance were observed. The exonuclease E415G mutation which is linked with piperaquine resistance was not reported.
Authors: Miriam K Laufer; Phillip C Thesing; Nicole D Eddington; Rhoda Masonga; Fraction K Dzinjalamala; Shannon L Takala; Terrie E Taylor; Christopher V Plowe Journal: N Engl J Med Date: 2006-11-09 Impact factor: 91.245
Authors: Steve M Taylor; Christian M Parobek; Derrick K DeConti; Kassoum Kayentao; Sheick Oumar Coulibaly; Brian M Greenwood; Harry Tagbor; John Williams; Kalifa Bojang; Fanta Njie; Meghna Desai; Simon Kariuki; Julie Gutman; Don P Mathanga; Andreas Mårtensson; Billy Ngasala; Melissa D Conrad; Philip J Rosenthal; Antoinette K Tshefu; Ann M Moormann; John M Vulule; Ogobara K Doumbo; Feiko O Ter Kuile; Steven R Meshnick; Jeffrey A Bailey; Jonathan J Juliano Journal: J Infect Dis Date: 2014-09-01 Impact factor: 5.226
Authors: Kevin Galinsky; Clarissa Valim; Arielle Salmier; Benoit de Thoisy; Lise Musset; Eric Legrand; Aubrey Faust; Mary Lynn Baniecki; Daouda Ndiaye; Rachel F Daniels; Daniel L Hartl; Pardis C Sabeti; Dyann F Wirth; Sarah K Volkman; Daniel E Neafsey Journal: Malar J Date: 2015-01-19 Impact factor: 2.979
Authors: Samuel O Oyola; Cristina V Ariani; William L Hamilton; Mihir Kekre; Lucas N Amenga-Etego; Anita Ghansah; Gavin G Rutledge; Seth Redmond; Magnus Manske; Dushyanth Jyothi; Chris G Jacob; Thomas D Otto; Kirk Rockett; Chris I Newbold; Matthew Berriman; Dominic P Kwiatkowski Journal: Malar J Date: 2016-12-20 Impact factor: 2.979
Authors: Moses Ocan; Fred Katabazi Ashaba; Savannah Mwesigwa; Kigozi Edgar; Moses R Kamya; Sam L Nsobya Journal: PLoS One Date: 2022-05-05 Impact factor: 3.752
Authors: Victor Osoti; Mercy Akinyi; Kevin Wamae; Kelvin M Kimenyi; Zaydah de Laurent; Leonard Ndwiga; Paul Gichuki; Collins Okoyo; Stella Kepha; Charles Mwandawiro; Regina Kandie; Philip Bejon; Robert W Snow; Lynette Isabella Ochola-Oyier Journal: Antimicrob Agents Chemother Date: 2022-03-10 Impact factor: 5.938
Authors: Nonlawat Boonyalai; Kirakarn Kirativanich; Chatchadaporn Thamnurak; Chantida Praditpol; Brian A Vesely; Mariusz Wojnarski; John S Griesenbeck; Norman C Waters Journal: Malar J Date: 2022-04-22 Impact factor: 3.469
Authors: Hugo O Valdivia; Fredy E Villena; Stephen E Lizewski; Jorge Garcia; Jackeline Alger; Danett K Bishop Journal: Sci Rep Date: 2020-12-01 Impact factor: 4.996